Who
Christina Rizopoulos Valauri
Director
Company insider
Files Form 4 as: Director, Precipio; Director, Tivic Health Systems.
In numbers
- Trades disclosed
- 21
- Buys
- 1
- Sells
- 0
- Bought
- $36K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 2 Jan 2024
- Last trade
- 15 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 19 Oct 2026 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $2,750122 at $22.54 | filing |
| 15 Jul 2026filed 16 Jul 2026 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $2,726108 at $25.24 | filing |
| 15 Jul 2026filed 16 Jul 2026 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $2,726108 at $25.24 | filing |
| 15 Apr 2026filed 17 Apr 2026 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $2,74393 at $29.49 | filing |
| 15 Apr 2026filed 17 Apr 2026 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $2,74393 at $29.49 | filing |
| 1 Apr 2026filed 2 Apr 2026 | Tivic Health SystemsBiotechnology | SEC FORM 4 Bought | $18K19,000 at $0.9478 | filing |
| 1 Apr 2026filed 2 Apr 2026 | VBIO Valion BioBiotechnology | SEC FORM 4 Bought | $18K19,000 at $0.95 | filing |
| 15 Jan 2026filed 20 Jan 2026 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $9,744406 at $24.00 | filing |
| 15 Jan 2026filed 20 Jan 2026 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $9,744406 at $24.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PRPO Precipiooption or derivative · Life-science tools | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PRPO Precipiooption or derivative · Life-science tools | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 6 Aug 2025filed 8 Aug 2025 | VBIO Valion Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 14 Jan 2025filed 16 Jan 2025 | PRPO Precipiooption or derivative · Life-science tools | SEC FORM 4 Code A | —1,000 at $0.00 | filing |
| 18 Dec 2024filed 20 Dec 2024 | VBIO Valion Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 15 Oct 2024filed 17 Oct 2024 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $9,7451,472 at $6.62 | filing |
| 9 Aug 2024filed 13 Aug 2024 | VBIO Valion Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 15 Jul 2024filed 16 Jul 2024 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $9,7372,103 at $4.63 | filing |
| 21 Jun 2024filed 25 Jun 2024 | PRPO Precipiooption or derivative · Life-science tools | SEC FORM 4 Code A | —1,000 at $0.00 | filing |
| 15 Apr 2024filed 17 Apr 2024 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $9,7461,446 at $6.74 | filing |
| 2 Jan 2024filed 4 Jan 2024 | PRPO Precipiooption or derivative · Life-science tools | SEC FORM 4 Code A | —103 at $0.00 | filing |
News
Valion Bio, Inc. Common Stock (NASDAQ:VBIO) vs. Arcus Biosciences (NYSE:RCUS) Head-To-Head ComparisonVBIO · themarketsdaily.com · 18 Oct 2026Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New ...VBIO · pr-inside.com · 9 Oct 2026Valion Bio, Inc.: Valion Bio: Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data CentersVBIO · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Christina Rizopoulos Valauri; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.